Article thumbnail

First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy

By Peter A. Anton, Terry Saunders, Julie Elliott, Elena Khanukhova, Robert Dennis, Amy Adler, Galen Cortina, Karen Tanner, John Boscardin, William G. Cumberland, Ying Zhou, Ana Ventuneac, Alex Carballo-Diéguez, Lorna Rabe, Timothy McCormick, Henry Gabelnick, Christine Mauck and Ian McGowan
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3182160
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2001). A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection.
  2. (2010). City Dept.of Helath and Mental Hygene
  3. (2000). Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue.
  4. (2010). Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation.
  5. (2010). Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.
  6. (2008). HIV infection and the gastrointestinal immune system.
  7. (2010). HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.
  8. (2000). Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines.
  9. (2008). Improving defences at the portal of HIV entry: mucosal and innate immunity.
  10. (2000). Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium.
  11. (2010). Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
  12. (1999). Safety and toxicity of nonoxynol-9 gel as a rectal microbicide.
  13. (2006). Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved?
  14. (2008). The use of highly active retroviral therapy to reduce HIV incidence at the population level.